You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

FOSAPREPITANT DIMEGLUMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Fosaprepitant Dimeglumine patents expire, and when can generic versions of Fosaprepitant Dimeglumine launch?

Fosaprepitant Dimeglumine is a drug marketed by Accord Hlthcare, Apotex, Arthur Grp, Aspiro, Baxter Hlthcare Corp, Be Pharms, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Lupin Ltd, MSN, Mylan Labs Ltd, Navinta Llc, Piramal Critical, Qilu Pharm Hainan, Sandoz, and Teva Pharms Usa. and is included in nineteen NDAs.

The generic ingredient in FOSAPREPITANT DIMEGLUMINE is fosaprepitant dimeglumine. There are eleven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Fosaprepitant Dimeglumine

A generic version of FOSAPREPITANT DIMEGLUMINE was approved as fosaprepitant dimeglumine by FRESENIUS KABI USA on June 9th, 2016.

  Try a Trial

Drug patent expirations by year for FOSAPREPITANT DIMEGLUMINE
Drug Prices for FOSAPREPITANT DIMEGLUMINE

See drug prices for FOSAPREPITANT DIMEGLUMINE

Recent Clinical Trials for FOSAPREPITANT DIMEGLUMINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fujian Shengdi Pharmaceutical Co., Ltd.Phase 3
Xijing HospitalN/A
University of LahorePhase 3

See all FOSAPREPITANT DIMEGLUMINE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for FOSAPREPITANT DIMEGLUMINE
Paragraph IV (Patent) Challenges for FOSAPREPITANT DIMEGLUMINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EMEND Injection fosaprepitant dimeglumine 150 mg/vial 022023 2 2012-01-25

US Patents and Regulatory Information for FOSAPREPITANT DIMEGLUMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 204025-001 Aug 26, 2020 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Qilu Pharm Hainan FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 213106-001 Sep 8, 2020 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Be Pharms FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 212309-001 Sep 5, 2019 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Arthur Grp FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 213199-001 Oct 4, 2021 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lupin Ltd FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 210689-001 Sep 5, 2019 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms Usa FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 210064-001 Sep 5, 2019 RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.